Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran: HELIOS-B

Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.

Lumasiran: Stability in Prepared Syringe

Standard response letter on the stability of lumasiran in a prepared syringe.

Vutrisiran: Drug Interactions

Standard response letter on vutrisiran and drug interactions.

Vutrisiran: Dosage & Administration Schedule Used in Phase 3 Studies

Standard response letter on the dosing schedules of vutrisiran used in the HELIOS-A and HELIOS-B studies.

Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study

Zilebesiran: Phase 2 Studies

Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.

Givosiran: Stability in Prepared Syringe

Standard response letter the stability of givosiran in a prepared syringe.

Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: Post hoc analyses from the phase 3 ENVISION study through month 36

Real-World Treatment Patterns in Participants with Transthyretin Amyloidosis with Polyneuropathy Enrolled in the ConTTRibute Registry

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6-months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.